High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy
J. Clin. Invest. David-Alexandre Gross, et al. 113:425 doi:10.1172/JCI19418 [Go to this article.]

Figure 1
Recognition of murine tumor cells by CTLs raised against mTERT peptides with high and low affinity for HLA-A*0201. (a) HHD mice were vaccinated with mTERT high-affinity peptides, and their spleen cells were restimulated in vitro 11 days later with the cognate peptide. CTLs were tested against RMAS/HHD cells loaded with an irrelevant (white bars) or the cognate peptide (light gray bars) at a 40:1 lymphocyte/target ratio. Results from one representative mouse per group are shown. (b) CTL₅₄₅, CTL₇₉₇, CTL₈₇₆ CTL₅₇₂, and CTL₉₈₈ lines were tested against RMAS/HHD loaded with an irrelevant or the cognate peptide, EL4S3-Rob, and EL4/HHD as indicated at a 20:1 lymphocyte/target ratio. (c) CTL₇₉₇ and CTL₅₇₂ lines were tested against RMAS/HHD loaded with an irrelevant or the cognate peptide, RMA, and RMA/HHD cells at a 20:1 lymphocyte/target ratio.